$11.19
+0.21 (+1.91%)
Open$11.25
Previous Close$10.98
Day High$11.48
Day Low$10.85
52W High$17.15
52W Low$9.85
Volume—
Avg Volume201.3K
Market Cap395.07M
P/E Ratio—
EPS$-1.11
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+140.1% upside
Current
$11.19
$11.19
Target
$26.87
$26.87
$21.20
$26.87 avg
$38.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 792.56M | 838.23M | 726.24M |
| Net Income | 29.18M | 25.09M | 21.12M |
| Profit Margin | 3.7% | 3.0% | 2.9% |
| EBITDA | 33.32M | 33.92M | 33.30M |
| Free Cash Flow | 24.79M | 28.65M | 30.31M |
| Rev Growth | +7.9% | +14.3% | -7.3% |
| Debt/Equity | 0.15 | 0.16 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |